ImmuneSensor Therapeutics
ImmuneSensor Therapeutics is a clinical-stage biotechnology company focused on developing novel medicines targeting the cGAS-STING pathway to modulate the innate immune system. Founded on groundbreaking discoveries by Dr. Zhijian Chen, the company aims to create best-in-class inhibitors and agonists to address unmet medical needs in inflammation, autoimmunity, and oncology.
Industries
Nr. of Employees
small (1-50)
ImmuneSensor Therapeutics
Patents
Products
IMSB301 (oral small-molecule cGAS inhibitor)
Orally available small-molecule inhibitor designed to selectively inhibit the cGAS enzyme to reduce pathological cGAS-driven inflammation; advanced into Phase 1 randomized, placebo-controlled, double-blind SAD/MAD clinical trial in healthy volunteers.
IMSA101 (STING agonist clinical candidate)
Small-molecule STING agonist advanced through Phase 1 monotherapy and combination cohorts with established RP2D and being evaluated in Phase 2 combination trials to stimulate antitumor immunity.
IMSB301 (oral small-molecule cGAS inhibitor)
Orally available small-molecule inhibitor designed to selectively inhibit the cGAS enzyme to reduce pathological cGAS-driven inflammation; advanced into Phase 1 randomized, placebo-controlled, double-blind SAD/MAD clinical trial in healthy volunteers.
IMSA101 (STING agonist clinical candidate)
Small-molecule STING agonist advanced through Phase 1 monotherapy and combination cohorts with established RP2D and being evaluated in Phase 2 combination trials to stimulate antitumor immunity.
Services
Planning and execution of first-in-human randomized, placebo-controlled, double-blind SAD and MAD clinical trials to evaluate safety, tolerability, PK and target engagement.
Small-molecule lead optimization, DMPK characterization and safety/toxicology studies to support candidate selection and regulatory submissions.
Development of ADC-based and other delivery platforms for targeted STING agonist delivery in oncology applications.
Planning and execution of first-in-human randomized, placebo-controlled, double-blind SAD and MAD clinical trials to evaluate safety, tolerability, PK and target engagement.
Small-molecule lead optimization, DMPK characterization and safety/toxicology studies to support candidate selection and regulatory submissions.
Development of ADC-based and other delivery platforms for targeted STING agonist delivery in oncology applications.
Expertise Areas
- cGAS–STING pathway therapeutics
- Small-molecule drug discovery and preclinical development
- Translational pharmacology and target engagement assays
- Phase 1 clinical development and early clinical design (SAD/MAD)
Key Technologies
- Small-molecule cGAS inhibitors
- STING agonist modalities
- Antibody-drug conjugate (ADC) delivery
- Ex vivo whole blood DNA stimulation assay
News & Updates
Tom Dubensky, Ph.D., President and CEO, will present a corporate update on September 19, 2024.
Awarded to Dr. Zhijian “James” Chen for the discovery of the cGAS enzyme.
Tom Dubensky, Ph.D., President and CEO, will present a corporate update on September 19, 2024.
Awarded to Dr. Zhijian “James” Chen for the discovery of the cGAS enzyme.